Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of “Buy” from Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPRGet Free Report) have been assigned an average rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $34.50.

Separately, HC Wainwright reiterated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday.

Get Our Latest Report on CAPR

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. boosted its stake in Capricor Therapeutics by 25.2% in the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock worth $1,040,000 after purchasing an additional 13,762 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Capricor Therapeutics in the third quarter valued at about $161,000. FMR LLC bought a new position in shares of Capricor Therapeutics in the third quarter valued at about $370,000. BNP Paribas Financial Markets lifted its position in Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after buying an additional 15,872 shares in the last quarter. Finally, Fred Alger Management LLC bought a new stake in Capricor Therapeutics during the 3rd quarter worth about $399,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Trading Down 2.6 %

CAPR stock opened at $12.88 on Tuesday. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The business’s 50 day moving average is $14.14 and its 200-day moving average is $14.46. The firm has a market cap of $585.65 million, a P/E ratio of -12.15 and a beta of 4.10.

About Capricor Therapeutics

(Get Free Report

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Read More

Analyst Recommendations for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.